EP Patent

EP4154904A1 — Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Assigned to Institut National de la Sante et de la Recherche Medicale INSERM · Expires 2023-03-29 · 3y expired

What this patent protects

Disclosed herein are methods for treating patients that may develop or already have preexisting gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate resid…

USPTO Abstract

Disclosed herein are methods for treating patients that may develop or already have preexisting gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4154904A1
Jurisdiction
EP
Classification
Expires
2023-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.